> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Submit Long Covid Drug as IND: FDA
- URL: https://www.fdaweb.com/submit-long-covid-drug-as-ind-fda/
- Published: 2024-06-12T12:00:00.000Z
- Updated: 2026-09-14T14:33:09.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5157160

FDA has recommended that Toronto, Canada’s Revive Therapeutics submit an IND for agency evaluation of the company’s bucillamine, described as an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long Covid. In a Type C [meeting](https://finance.yahoo.com/news/revive-therapeutics-provides-fda-type-130500085.html?ref=fdaweb.com) with company executives, FDA officials said the new IND may cross-reference applicable sections from Revive’s current IND that evaluated in a Phase 3 trial bucillamine’s safety and effectiveness in treating patients with mild to moderate Covid-19.

Revive says that during the meeting FDA also provided feedback on the appropriate design, study population, and safety and efficacy measures for assessing a therapeutic benefit in patients with Long Covid.

In 7/2023, the company released positive results from the Phase 3 trial in patients with mild to moderate Covid-19.